SMCD
MCID: SYS004
MIFTS: 60

Systemic Mastocytosis (SMCD) malady

Categories: Rare diseases, Blood diseases

Aliases & Classifications for Systemic Mastocytosis

About this section

Aliases & Descriptions for Systemic Mastocytosis:

Name: Systemic Mastocytosis 35 11 48 13
Systemic Mast Cell Disease 48 27
Mastocytosis, Systemic 39 68
Corneal Dystrophy, Subepithelial Mucinous 68
 
Systemic Tissue Mast Cell Disease 11
Smcd - Systemic Mast Cell Disease 11
Mastocytosis Systemic 50
Smcd 48

Classifications:



External Ids:

Disease Ontology11 DOID:349
MeSH39 D034721
NCIt45 C9235

Summaries for Systemic Mastocytosis

About this section
NIH Rare Diseases:48 Systemic mastocytosis (sm) is a form of mastocytosis in which mast cells accumulate in internal tissues and organs such as the liver, spleen, bone marrow, and small intestines. it is typically diagnosed in adults. signs and symptoms vary based on which parts of the body are affected. the disorder is usually caused by somatic changes (mutations) in the kit gene. most cases are sporadic and not inherited, but familial cases rarely have been reported.  systemic mastocytosis can be divided into 4 main categories which are distinguished by various features:indolent systemic mastocytosis (ism) systemic mastocytosis with an associated hematologic nonmast cell lineage disorder (sm-ahnmd) aggressive systemic mastocytosis (asm) mast cell leukemia (mcl) once a person is diagnosed, the category of sm must be determined, as treatment and prognosis differ for each. last updated: 9/6/2016

MalaCards based summary: Systemic Mastocytosis, also known as systemic mast cell disease, is related to indolent systemic mastocytosis and aggressive systemic mastocytosis, and has symptoms including osteoporosis, skin rash and urticaria. An important gene associated with Systemic Mastocytosis is KIT (KIT Proto-Oncogene Receptor Tyrosine Kinase), and among its related pathways are Regulation of KIT signaling and Cytoskeleton remodeling_Role of PDGFs in cell migration. Affiliated tissues include bone, bone marrow and liver, and related mouse phenotypes are Decreased viability and limbs/digits/tail.

Related Diseases for Systemic Mastocytosis

About this section

Diseases in the Mastocytosis family:

systemic mastocytosis

Diseases related to Systemic Mastocytosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 165)
idRelated DiseaseScoreTop Affiliating Genes
1indolent systemic mastocytosis12.1
2aggressive systemic mastocytosis12.1
3smouldering systemic mastocytosis12.0
4systemic mastocytosis with an associated clonal hematologic non-mast cell lineage disease12.0
5mastocytosis11.6
6corneal dystrophy, subepithelial mucinous11.5
7sm-ahnmd11.5
8metaphyseal chondrodysplasia, schmid type11.4
9mast-cell leukemia11.2
10maculopapular cutaneous mastocytosis10.8
11monoclonal mast cell activation syndrome10.8
12leukemia10.4
13invasive mole10.2KIT, PDGFRA
14amaurosis congenita, cone-rod type, with congenital hypertrichosis10.2KIT, PDGFRA
15freemartinism10.2CD2, KIT
16larynx leiomyosarcoma10.2KIT, PDGFRA
17high grade b-cell lymphoma with rearrangements of myc and bcl2 and/or bcl610.2KIT, KITLG
18cough variant asthma10.2KIT, KITLG
19acute respiratory distress syndrome10.2JAK2, KIT
20congenital disorder of glycosylation, type iq10.2IFNA2, KIT, TET2
21hemangioma of peripheral nerve10.2IFNA2, KIT, KITLG
22osteoporosis10.2
23malignant epithelial mesothelioma10.2IFNA2, KIT, PDGFRA
24rectum leiomyoma10.2KIT, PDGFRA
25osteogenesis imperfecta, type viii10.2JAK2, TET2
26spondylocostal dysostosis 210.2IFNA2, JAK2
27pustulosis palmaris et plantaris10.1KIT, PDGFRA
28restrictive cardiomyopathy10.1FIP1L1, PDGFRA
29dentinogenesis imperfecta, shields type ii10.1KIT, KITLG, PDGFRA
30lagophthalmos10.1FIP1L1, PDGFRA
31regional odontodysplasia10.1ASXL1, TET2
32pericoronitis10.1HDC, KIT, KITLG
33kidney rhabdoid cancer10.1CD2, KIT, KITLG
34myeloid leukemia10.1
35weaver syndrome10.1FIP1L1, PDGFRA
36kidney clear cell sarcoma10.1KIT, PDGFRA
37intracranial sinus thrombosis10.1FIP1L1, KIT, KITLG
38cerebral arterial disease10.1KIT, PDGFRA
39agammaglobulinemia 8, autosomal dominant10.1JAK2, KIT
40intestinal impaction10.1JAK2, KITLG, TET2
41lymphoma10.1
42urticaria pigmentosa10.1
43urticaria10.1
44myofibromatosis, infantile, 110.1IFNA2, PDGFRB
45oral leukoedema10.1FGFR1, KIT, PDGFRA
46neuromyelitis optica10.0IFNA2, JAK2, KIT, TET2
47fragile x-associated tremor/ataxia syndrome10.0KIT, PDGFRA
48von hippel anomaly10.0ASXL1, JAK2, TET2
49thrombophilia due to activated protein c resistance10.0FIP1L1, JAK2, PDGFRA
50dfnb110.0KIT, PDGFRA, PDGFRB

Graphical network of the top 20 diseases related to Systemic Mastocytosis:



Diseases related to systemic mastocytosis

Symptoms & Phenotypes for Systemic Mastocytosis

About this section

Human phenotypes related to Systemic Mastocytosis:

 64 (show all 31)
id Description HPO Frequency HPO Source Accession
1 osteoporosis64 HP:0000939
2 skin rash64 HP:0000988
3 urticaria64 HP:0001025
4 cirrhosis64 HP:0001394
5 portal hypertension64 HP:0001409
6 ascites64 HP:0001541
7 sudden cardiac death64 HP:0001645
8 splenomegaly64 HP:0001744
9 thrombocytopenia64 HP:0001873
10 abnormality of eosinophils64 HP:0001879
11 leukopenia64 HP:0001882
12 anemia64 HP:0001903
13 nausea and vomiting64 HP:0002017
14 malabsorption64 HP:0002024
15 abdominal pain64 HP:0002027
16 asthma64 HP:0002099
17 hepatomegaly64 HP:0002240
18 headache64 HP:0002315
19 acute leukemia64 HP:0002488
20 bone pain64 HP:0002653
21 lymphadenopathy64 HP:0002716
22 recurrent fractures64 HP:0002757
23 osteolysis64 HP:0002797
24 arthralgia64 HP:0002829
25 myalgia64 HP:0003326
26 abnormality of the gastric mucosa64 HP:0004295
27 bone marrow hypocellularity64 HP:0005528
28 chronic leukemia64 HP:0005558
29 generalized osteosclerosis64 HP:0005789
30 impaired temperature sensation64 HP:0010829
31 mastocytosis64 HP:0100495

GenomeRNAi Phenotypes related to Systemic Mastocytosis according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00381-A-110.0FGFR1, KIT, PDGFRA, PDGFRB

MGI Mouse Phenotypes related to Systemic Mastocytosis according to GeneCards Suite gene sharing:

41 (show all 13)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053719.7FGFR1, KIT, KITLG, PDGFRA, PDGFRB
2MP:00053809.4FGFR1, JAK2, KIT, KITLG, PDGFRA, PDGFRB
3MP:00053829.2ASXL1, FGFR1, KIT, KITLG, PDGFRA, PDGFRB
4MP:00053819.2ASXL1, FGFR1, KIT, KITLG, PDGFRA, PDGFRB
5MP:00107718.8FGFR1, HDC, JAK2, KIT, KITLG, PDGFRA
6MP:00020068.7ASXL1, JAK2, KIT, KITLG, PDGFRA, TET2
7MP:00028738.2CD2, FGFR1, JAK2, KIT, PDGFRA, PDGFRB
8MP:00053848.0ASXL1, FGFR1, JAK2, KIT, KITLG, PDGFRA
9MP:00053798.0ASXL1, FGFR1, JAK2, KIT, KITLG, PDGFRA
10MP:00053908.0ASXL1, FGFR1, JAK2, KIT, KITLG, PDGFRA
11MP:00053787.5ASXL1, FGFR1, HDC, JAK2, KIT, KITLG
12MP:00053977.5ASXL1, FGFR1, HDC, JAK2, KIT, KITLG
13MP:00053877.5ASXL1, FGFR1, HDC, JAK2, KIT, KITLG

Drugs & Therapeutics for Systemic Mastocytosis

About this section

Drugs for Systemic Mastocytosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 71)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1Protein Kinase InhibitorsPhase 4, Phase 2, Phase 13689
2Imatinib MesylatePhase 4, Phase 2, Phase 1600123596
3
Cladribineapproved, investigationalPhase 2, Phase 3734291-63-820279
Synonyms:
(2R,3S,5R)-5-(6-amino-2-Chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol
(2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol
2 Chlorodeoxyadenosine
2'-Deoxy-2-chloroadenosine
2-CdA
2-Chloro-2'-deoxy-beta-adenosine
2-Chloro-2'-deoxyadenosine
2-Chloro-6-amino-9-(2-deoxy-beta-D-erythropentofuranosyl)purine
2-Chlorodeoxyadenosine
2-chloro-6-amino-9-(2-Deoxy-beta-D-erythro-pentofuranosyl)purine
2-chloro-6-amino-9-(2-deoxy-beta-D-erythro-pentofuranosyl)purine
2-chloro-Deoxyadenosine
2-chloro-deoxyadenosine
24757-90-2
2CdA
2ClAdo
4291-63-8
AC-7591
AC1L2FXP
Adenosine, 2-chloro-2'-deoxy
BRN 0624220
C10H12ClN5O3.C3H8
CHEBI:567361
CHEMBL1619
CID20279
CL9
CPD000058553
Chlorodeoxyadenosine
Cladarabine
Cladaribine
Cladribina
Cladribine
Cladribine (JAN/USAN/INN)
Cladribine [USAN:INN:BAN]
Cladribinum
 
CldAdo
D01370
D017338
DB00242
FT-0080707
HMS2052K13
HSDB 7564
LS-15109
Leustat
Leustatin
Leustatin (TN)
Leustatin, 2-chlorodeoxyadenosine, Cladribine
Litak
MLS000028377
MLS000028484
MLS000759397
MLS001077345
MolPort-002-054-532
MolPort-005-935-074
Movectro
Mylinax
NCGC00022567-05
NCGC00164384-01
NSC 105014
NSC 105014-F
NSC-105014
RWJ 26251
RWJ-26251
RWJ-26251-000
S1199_Selleck
SAM001246526
SMR000058553
UNII-47M74X9YT5
ZINC03798064
cladribina
cladribine
cladribinum
4Immunosuppressive AgentsPhase 2, Phase 3, Phase 113086
52-chloro-3'-deoxyadenosinePhase 2, Phase 332
6
Sunitinibapproved, investigationalPhase 2, Phase 1510341031-54-7, 557795-19-45329102
Synonyms:
(2S)-2-hydroxybutanedioic acid
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
326914-13-0
341031-54-7
5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE
557795-19-4
AC1NS62J
AC1O5CMQ
AKOS005145765
Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1)
CHEBI:38940
CHEBI:550864
CHEMBL1567
CHEMBL535
CID5329102
CID6456015
D06402
D08552
DB01268
DB07417
EN002687
FT-0083555
FT-0083556
I01-1229
K00588a
KS-5022
LS-186078
LS-187023
LS-187648
MolPort-003-986-763
N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate
N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
NCGC00164631-01
 
NSC736511
NSC750690
PDGF TK antagonist
PHA-290940AD
PNU-290940AD
S1042_Selleck
ST51053712
SU 011248
SU 11248
SU-010398
SU-011248 L-malate salt
SU-11248
SU-11248 L-malate salt
SU-11248J
SU-12662
SU010398
SU011248
SU011248 L-malate salt
SU11248
Su-011248
Sunitanib
Sunitinib
Sunitinib (INN)
Sunitinib (free base)
Sunitinib malate
Sunitinib malate (JAN/USAN)
Sunitinib malate [USAN]
Sunitinibum
Sutent
Sutent (TN)
Sutent, SU-11248
TL8002546
UNII-LVX8N1UT73
UNII-V99T50803M
sunitinib
sunitinibum
7
Dasatinibapproved, investigationalPhase 2285302962-49-83062316
Synonyms:
(18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
1N1
2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide
302962-49-8
AC1MI3ET
AC1Q2P0C
AmbotzLS-1203
Anhydrous dasatinib
BCB03_000715
BMS 354825
BMS dasatinib
BMS-354825
BMS-354825, Sprycel, BMS354825, Dasatinib
BMS354825
C488369
CHEBI:49375
CHEMBL1421
CID3062316
D03658
DB01254
Dasatinib
Dasatinib (USAN)
Dasatinib (anh.)
Dasatinib [USAN]
Dasatinib anhydrous
Dasatinib, BMS 354825
Dasatinibum
EC-000.2122
 
EN002710
FT-0084503
I14-1972
Kinome_3650
LS-186641
LS-187028
LS-187773
MolPort-003-846-143
N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE
N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, monohydrate
N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide
N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide
NCGC00181129-01
NSC-732517
NSC732517
S1021_Selleck
SPRYCEL (TN)
Sprycel
Spyrcel
UNII-X78UG0A0RN
anh. dasatinib
dasatinib
dasatinib (anhydrous)
dasatinibum
nchembio.117-comp11
nchembio.162-comp4
nchembio.332-comp1
8
Cyclophosphamideapproved, investigationalPhase 2293550-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Anhydrous cyclophosphamide
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
 
DB00531
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
9
Sirolimusapproved, investigationalPhase 2194053123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
10
Denileukin diftitoxapproved, investigationalPhase 247173146-27-5
Synonyms:
DT
Diphtheria toxin precursor
 
NAD(+--diphthamide ADP- ribosyltransferase)
Ontak
denileukin diftitox
11
Cyclosporineapproved, investigational, vet_approvedPhase 2, Phase 192279217-60-0, 59865-13-35284373, 6435893
Synonyms:
1c5f
1cyn
30024_FLUKA
30024_SIGMA
59865-13-3
79217-60-0
AC1L1EQW
AC1NQXJE
AC1NR4C4
AC1NUQK3
AC1NUZNC
AC1O5KOG
AC1Q2UDG
Ambap59865-13-3
Ambotz59865-13-3
Antibiotic S 7481F1
BMT-ABA-SAR-MLE-VAL-MLE-ALA-ALA-MLE-MLE-MVA
BMT-ABA-SAR-MLE-VAL-MLE-ALA-DAL-MLE-MLE-MVA
BPBio1_000496
BRD-A64290322-001-01-6
BRD-A69815203-001-04-3
BRD-K13533483-001-03-0
BSPBio_000450
BSPBio_001596
BSPBio_003186
C 3662
C05086
C1832_SIGMA
C3662_SIGMA
C62H111N11O12
CB-01-09 MMX
CHEBI:106343
CHEBI:328305
CHEBI:4031
CHEMBL160
CHEMBL386389
CHEMBL532318
CID2909
CID5280754
CID5284373
CID5458585
CID5497195
CID6435893
CSA
CYCLOSPORIN A (SEE ALSO TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A))
CYCLOSPORIN A, USP
Ciclosporin
Ciclosporin (JP15)
Ciclosporina
Ciclosporine
Ciclosporinum
Cipol N
Cipol-N
Consupren
Consupren S
CsA
CsA & IFN.alpha.
CyA
Cyclokat
Cyclosporin
Cyclosporin A
Cyclosporin A & IFN.alpha.
Cyclosporin A Implant
Cyclosporin A, Tolypocladium inflatum
Cyclosporine (USP)
Cyclosporine A
Cyclosporine [USAN]
D00184
DE-076
DivK1c_000871
EU-0100242
Equoral
GNF-Pf-2808
Gengraf
Gengraf (TN)
HMS1569G12
HMS1791P18
HMS1921L20
HMS1989P18
HMS2089A09
HMS2092F06
HMS502L13
Helv Chim Acta 60: 1568 (1977)
 
I06-0379
I06-0966
IDI1_000871
KBio1_000871
KBio2_000780
KBio2_003348
KBio2_005916
KBio3_002686
KBioGR_001898
KBioSS_000780
LMPK14000003
LS-257
LS-58836
Lopac0_000242
MLS000028376
MLS001333756
MLS002153454
MLS002207033
Mitogard
Modusik-A
MolPort-000-760-988
MolPort-005-934-008
MolPort-006-705-994
NCGC00093704-01
NCGC00093704-02
NCGC00093704-03
NCGC00093704-04
NCGC00093704-05
NCGC00093704-06
NCGC00093704-07
NCGC00093704-08
NCGC00164258-01
NCGC00164258-02
NINDS_000871
NSC290193
Neoplanta
Neoral
Neoral (TN)
NeuroSTAT
Nova-22007
OL 27-400
OL-27400
OLO-400
Papilock
Prestwick2_000435
Prestwick3_000435
Prestwick_731
Pulminiq
Ramihyphin A
Restasis
Restasis (TN)
S-Neoral
S1514_Selleck
SDZ-OXL 400
SMR000058578
SPBio_001467
SPECTRUM1502202
ST-603
Sandimmun
Sandimmun Neoral
Sandimmune
Sandimmune (TN)
Sandimmune, Gengraf, Restasis, Atopica, Sangcya, Cyclosporine
Sang-2000
Sang-35
SangCyA
Sangcya
Sigmasporin
Sigmasporin Microoral
Spectrum2_001484
Spectrum3_001593
Spectrum4_001279
Spectrum5_001628
Spectrum_000300
TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A)
Vekacia
Zyclorin
cyclophorine
cyclosporin A
cyclosporine
from Tolypocladium inflatum (Trichoderma polysporin)
nchembio.184-comp6
nchembio.301-comp5
nchembio.342-comp1
12
Paclitaxelapproved, vet_approvedPhase 2286433069-62-436314
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-Epi-Paclitaxel
7-Epi-Taxol
7-Epipaclitaxel
7-Epitaxol
7-epi-Paclitaxel
7-epi-Taxol
AB00513812
ABI 007
ABI-007
ABI007
AC-675
AC1L1IOG
AC1L1VJI
AC1L9AVF
ACon1_002231
ANX-513
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
Ambotz33069-62-4
Anzatax
Asotax
BIDD:PXR0046
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
BSPBio_000290
BSPBio_001152
BSPBio_002614
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
Bristaxol
C07394
C466458
C47H51NO14
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
CPD-8718
Capxol
D00491
DB01229
DHP-107
DHP-208
DRG-0190
DTS-301
DivK1c_000441
EU-0101201
Ebetaxel
EmPAC
Epitaxol
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
 
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LMPR0104390001
LS-31070
LipoPac
Lopac0_001201
MBT 0206
MEGxp0_001940
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MPI-5018
Micellar Paclitaxel
Mitotax
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
NCI60_000601
NINDS_000441
NK 105
NP-010981
NSC 125973
NSC-125973
NSC125973
NSC358882
Nanotaxel
Neuro_000060
Nova-12005
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S-8184 Paclitaxel Injectable Emulsion
S1150_Selleck
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
SPECTRUM1503908
ST50306996
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
Spectrum_001536
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TAXOL (TN)
TAXOL, 10-EPI,
TXL
TaxAlbin
Taxol
Taxol A
Taxol Konzentrat
Taxol.RTM. (Registered Trademark)
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
Xorane
Yewtaxan
abi-007
albumin-bound paclitaxel
cMAP_000068
nab-paclitaxel
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
paclitaxel
weekly paclitaxel
13
alemtuzumabapproved, investigationalPhase 2310216503-57-0
Synonyms:
Campath
 
MabCampath
alemtuzumab
14
rituximabapprovedPhase 21692174722-31-710201696
Synonyms:
AntiCD20
IDEC-102
IDEC-C2B8
 
Ig gamma-1 chain C region
MabThera
Mabthera
Rituxan
rituximab
15
Miconazoleapproved, investigational, vet_approvedPhase 2, Phase 1370622916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
16
FludarabineapprovedPhase 2, Phase 1115421679-14-1, 75607-67-930751
Synonyms:
(2R,3S,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
(2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
2-F-ARAA
2-F-ara-A
2-Fluoro Ara-A
2-Fluoro-9-beta-D-arabinofuranosyladenine
2-fluoro ARA-A
21679-14-1
9-beta-D-Arabinofuranosyl-2-fluoroadenine
9-beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine
9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro- (9CI)
AC1LCW8I
AC1Q51CF
C10H12FN5O4
CCRIS 3382
CHEMBL1568
CID657237
CPD000058874
D07966
EINECS 244-525-5
F-Ara-A
FAMP
FT-0082766
FaraA
Fludara
Fludara, Fludarabine
 
Fludarabina
Fludarabina [Spanish]
Fludarabine
Fludarabine (INN)
Fludarabine 5'-monophosphate
Fludarabine [INN]
Fludarabine monophosphate
Fludarabine phosphate
Fludarabinum
Fludarabinum [Latin]
Fludura
Fluradosa
Fluradosa (TN)
HSDB 6964
I14-4978
LS-15061
MLS000028687
NSC 118218
NSC 118218H
NSC-118218
S1491_Selleck
SAM002548956
SMR000058874
SQ Fludarabine
UNII-1X9VK9O1SC
UNII-P2K93U8740
ZINC04216238
17
EverolimusapprovedPhase 21940159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
everolimus
18
VidarabineapprovedPhase 2, Phase 152124356-66-932326, 21704
Synonyms:
(+)-Cyclaradine
.beta.-Adenosine
.beta.-D-Adenosine
1odi
2-(6-AMINO-purin-9-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol
2946-52-3
2fqy
2gl0
30143-02-3
3080-29-3
3228-71-5
4005-33-8
46946-45-6
46969-16-8
524-69-6
5536-17-4
58-61-7
9-Arabinosyladenine
9-beta-D-Arabinofuranosyl-9H-purin-6-amine
9-beta-D-Arabinofuranosyl-adenine
9-beta-D-Arabinofuranosyladenine
9-beta-D-arabinofuranosyl-adenine
9-β-D-arabinofuranosyl-9H-purin-6-amine
9-β-D-arabinofuranosyladenine
A 9251
A0152
A4036_SIGMA
A4676_SIGMA
A5762_SIGMA
A9251_SIGMA
AC1L18OL
AC1L1U8O
AC1L2IWM
AC1L2SCM
AC1O4WIN
AC1O8PY7
AC1Q1ID3
AC1Q4Y1Z
AC1Q52XU
ADENOSINE, U.S.P.
ADN
AI3-52413
AI3-52821
AR-1H6029
ARA-A NSC 247519
Ade-Rib
Adenine Arabinoside
Adenine arabinoside
Adenine nucleoside
Adenine riboside
Adenine xyloside
Adenocard
Adenocard (TN)
Adenocard, Adenosine
Adenocor
Adenoscan
Adenoscan (TN)
Adenosin
Adenosin [German]
Adenosine (JAN/USP)
Adenosine [USAN:BAN]
Adenosine arabinose
Adenosine-8-14C
Adensoine
Ambap5536-17-4
Ara A
Ara-A
Ara-ATP
Araadenosine
Arabinoside Adenine
Arabinoside adenine
Arabinosyl Adenine
Arabinosyl adenine
Arabinosyl-adenine
Arabinosyladenine
Arasena-A
Armes
Armes (TN)
BB_NC-0565
BPBio1_000898
BRN 0624881
BSPBio_000816
BSPBio_001796
BSPBio_002000
Bio1_000437
Bio1_000926
Bio1_001415
Boniton
C00212
CAS-5536-17-4
CCRIS 2557
CCRIS 3383
CHEBI:136932
CHEBI:16335
CHEBI:45327
CHEMBL1090
CHEMBL20247
CHEMBL477
CI 673
CI-673
CID102198
CID191
CID21704
CID60961
CID6420052
CID6713976
CPD000471872
Caswell No. 010B
D000241
D00045
D06298
DB00640
DivK1c_000191
EINECS 200-389-9
EINECS 217-911-6
EINECS 226-893-9
EU-0100123
FT-0082881
HMS1570I18
HMS1920A13
HMS1921K05
HMS2090F06
HMS2091G13
HMS2092C16
HMS500J13
HSDB 6514
 
I01-1121
IDI1_000191
KBio1_000191
KBio2_002418
KBio2_004986
KBio2_007554
KBio3_001296
KBio3_001500
KBioGR_001224
KBioSS_002424
L000094
LS-15059
LS-15085
Lopac0_000123
MEDR-640
MLS000069638
MLS000699527
MLS001066352
MLS001333133
MLS001333134
MLS002153227
MLS002153992
MolPort-001-785-903
MolPort-001-838-229
MolPort-003-666-308
Myocol
NCGC00016656-01
NCGC00023673-03
NCGC00023673-04
NCGC00023673-05
NCGC00023673-06
NCGC00023673-07
NCGC00094579-01
NCGC00094579-02
NCGC00094579-03
NCGC00094579-04
NCGC00178869-01
NCGC00179417-01
NCI60_003823
NCI60_037192
NCIOpen2_003303
NCIOpen2_005376
NINDS_000191
NSC 247519
NSC 404241
NSC 627048
NSC 7359
NSC 7652
NSC-404241
NSC247519
NSC404241
NSC627048
NSC70422
NSC7359
NSC7652
NSC80832
NSC87676
NSC91041
Nucleocardyl
PDSP1_001036
PDSP2_001020
Pallacor
Polyadenosine
Polyriboadenosine
Prestwick0_000768
Prestwick1_000768
Prestwick2_000768
Prestwick3_000768
Prestwick_983
RAB
S1647_Selleck
S1784_Selleck
SAM002564191
SMP1_000312
SMR000058216
SMR000225041
SMR000471872
SMR001233326
SPBio_001194
SPBio_001491
SPBio_002755
SPECTRUM1500107
SPECTRUM1500609
SR 96225
SR-96225
STK361815
SUN-Y4001
Sandesin
Spectrum2_001257
Spectrum2_001336
Spectrum3_000288
Spectrum3_000580
Spectrum4_000782
Spectrum5_001429
Spectrum_001894
Spongoadenosine
TL8003749
UNII-3XQD2MEW34
UNII-K72T3FS567
USAF CB-10
V0098
VIRDARABINE
Vidarabin
Vidarabina
Vidarabina [DCIT]
Vidarabine
Vidarabine (JAN)
Vidarabine anhydrous
Vidarabinum
Vira ATM
Vira-A
Vira-A, Vidarabine
XA
Xylosyl A
Xylosyladenine
ZINC00970363
ZINC02169830
adenine-D-ribose
adenosine
alpha-Ara A
beta-Adenosine
beta-Ara A
beta-D-Adenosine
bmse000061
nchembio.143-comp9
nchembio.186-comp109
nchembio.64-comp4
nchembio706-5
19
Mycophenolic acidapprovedPhase 2, Phase 195224280-93-1446541
Synonyms:
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
Acide mycophenolique
Acido micofenolico
Acidum mycophenolicum
 
Melbex
Micofenolico acido
Mycophenoic acid
Mycophenolate
Mycophenolsäure
Myfortic
20
Mycophenolate mofetilapproved, investigationalPhase 2, Phase 1952128794-94-55281078
Synonyms:
115007-34-6
128794-94-5
140401-05-4
2-Morpholinoethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (e)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate
2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate
4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl -3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E)
AC-1562
AC1NQXZW
AC1Q6O6X
AR-1J6939
BB_NC-2566
C07908
C23H31NO7
CHEMBL1456
CID5281078
CellCept
CellCept, RS 61443, TM-MMF, Mycophenolate mofetil
Cellcept
Cellcept (TN)
D00752
DB00688
HMS2090A03
 
HSDB 7436
I01-0898
I06-1947
LS-172272
LS-75572
ME-MPA
MMF
MMF CellCept(TM)
MolPort-000-883-800
Munoloc
Mycophenolate mofetil (JAN/USAN)
Mycophenolic acid morpholinoethyl ester
Mycophenylate mofetil
NCGC00159459-02
NCGC00159459-03
NSC724229
R-99
RS 61443
RS-61443
RS-61443-190
S1501_Selleck
TL8000648
TM-MMF
UNII-9242ECW6R0
ZINC21297660
mycophenolate mofetil
21StaurosporineexperimentalPhase 24762996-74-1
22Angiogenesis Modulating AgentsPhase 2, Phase 14185
23Angiogenesis InhibitorsPhase 2, Phase 14257
24Specific substance maruyamaPhase 215
254'-N-benzoylstaurosporinePhase 225
26Antimetabolites, AntineoplasticPhase 2, Phase 17361
27Antibodies, MonoclonalPhase 24039
28Antiviral AgentsPhase 2, Phase 19967
29ImmunoglobulinsPhase 26394
30Dermatologic AgentsPhase 2, Phase 15806
31Calcineurin InhibitorsPhase 2, Phase 11622
32AntibodiesPhase 26394
33Vidarabine PhosphatePhase 2, Phase 1127
34AntimetabolitesPhase 2, Phase 112054
35Anti-Infective AgentsPhase 2, Phase 122062
36AnalgesicsPhase 211733
37Antibiotics, AntitubercularPhase 2, Phase 17180
38Anti-Bacterial AgentsPhase 2, Phase 111226
39Antirheumatic AgentsPhase 2, Phase 110956
40Analgesics, Non-NarcoticPhase 26501
41Antifungal AgentsPhase 2, Phase 13696
42Albumin-Bound PaclitaxelPhase 22864
43Interleukin-2Phase 2571
44Cromolyn SodiumPhase 217
45Peripheral Nervous System AgentsPhase 223689
46tyrosineNutraceuticalPhase 2699
47
Tamoxifenapproved39010540-29-12733526
Synonyms:
(Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene
(Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine
(Z)-2-(4-(1,2-diphenylbut-1-enyl)phenoxy)-N,N-dimethylethanamine
(Z)-2-(Para-(1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine
(Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine (IUPAC)
(Z)-2-[4-(1,2)-DIPHENYL-1-BUTENYL)-PHENOXY]-N,N-DIMETHYLETHANAMINE
(Z)-2-[p-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine
,citrate
1-P-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-Para-beta-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-.beta.-Dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
10540-29-1
1ya4
2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine
2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine
54965-24-1 (citrate)
AC1MBZ3R
Apo-Tamox
Apo-tamox
BIDD:ER0008
BIDD:GT0009
BIDD:PXR0003
BPBio1_000278
BRD-K93754473-001-02-9
BRD-K93754473-048-05-3
BSPBio_000252
BSPBio_001150
BSPBio_001982
C07108
C26H29NO
CCRIS 3275
CHEBI:41774
CHEMBL83
CID2733526
Citofen
Crisafeno
D08559
DB00675
Diemon
EINECS 234-118-0
Gen-Tamoxifen
Gen-tamoxifen
HMS1362J11
HMS1792J11
HMS1990J11
HMS2090N08
HSDB 6782
ICI 47699
ICI-46,474
ICI-47699
IDI1_000258
IDI1_002170
Istubol
Kessar
L024126
LS-393
Lopac0_001203
MLS001332535
MLS001332536
MolPort-003-850-384
 
NCGC00024928-01
NCGC00024928-03
NCGC00024928-04
NCGC00024928-05
NCGC00024928-07
NCGC00024928-08
NCGC00024928-09
NCGC00024928-12
NSC727681
Noltam
Nolvadex
Nolvadex-D
Nourytam
Novaldex
Novo-Tamoxifen
Oncomox
PMS-Tamoxifen
Pms-Tamoxifen
Prestwick2_000146
Prestwick3_000146
QTL1_000079
Retaxim
SMR000059172
ST50511785
Spectrum5_001417
Spectrum5_002043
T5648_SIGMA
TAMOXIFEN (TAMOXIFEN CITRATE (54965-24-1))
TRANS FORM OF TAMOXIFEN
Tamizam
Tamofen
Tamone
Tamoplex (TN)
Tamoxasta
Tamoxen
Tamoxifen
Tamoxifen (INN)
Tamoxifen (TN)
Tamoxifen (Z)
Tamoxifen Citrate
Tamoxifen [INN:BAN]
Tamoxifen and its salts
Tamoxifene
Tamoxifene [INN-French]
Tamoxifeno
Tamoxifeno [INN-Spanish]
Tamoxifenum
Tamoxifenum [INN-Latin]
Tamoxifène
Tocris-0999
Tomaxithen
Trans-Tamoxifen
UNII-094ZI81Y45
UPCMLD-DP027
Valodex
Zemide
cMAP_000044
nchembio.140-comp7
nchembio.76-comp1
nchembio732-comp3
tamoxifen
trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine
trans-Tamoxifen
48
Foscarnetapproved3363585-09-1, 4428-95-93415
Synonyms:
1nki
34156-56-4
4428-95-9
4428-95-9 (Parent)
63585-09-1
63585-09-1 (tri-hydrochloride salt)
79510_FLUKA
A 29622
A-29622
AC-2085
AC1L1FVT
AC1L2C37
AC1L5400
AC1NB82R
AC1Q1UNV
AR-1L5079
Ambap63585-09-1
BSPBio_003067
C06456
CHEBI:127780
CHEBI:141644
CHEBI:60269
CHEMBL666
CHEMBL754
CID169569
CID3415
CID44561
Carboxyphosphonic acid
D00579
D02267
DB00529
DRG-0017
Dihydroxyphosphinecarboxylic acid oxide
Dihydroxyphosphinecarboxylic acid oxide and MSL, neutralizing monoclonal antibody
Dihydroxyphosphinecarboxylic acid oxide trisodium salt
Dihydroxyphosphinecarboxylic acid oxide trisodium salt hexahydrate
DivK1c_000915
EHB 776
EHB-776
FOSCARNET SODIUM
Formic acid, phosphono-, trisodium salt, hexahydrate
Forscarnet sodium
Foscarmet
Foscarnet & IFN-.ALPHA.
Foscarnet sodico
Foscarnet sodico [Spanish]
Foscarnet sodique
Foscarnet sodique [French]
Foscarnet sodique [INN-French]
Foscarnet sodium (USAN/INN)
Foscarnet sodium [USAN:INN:BAN]
Foscarnet sodium hydrate
Foscarnet sodium hydrate (JAN)
Foscarneto sodico
Foscarneto sodico [INN-Spanish]
Foscarnetum natricum
Foscarnetum natricum [INN-Latin]
Foscarnetum natricum [Latin]
Foscavir
Foscavir (TN)
HMS1921D18
HMS2092N15
HMS502N17
 
HS-0008
IDI1_000915
KBio1_000915
KBio2_001839
KBio2_004407
KBio2_006975
KBio3_002567
KBioGR_001419
KBioSS_001839
LS-105952
LS-105953
LS-183979
LS-187063
LS-187793
MSL & PFA
MolPort-003-665-560
MolPort-003-895-968
NCGC00094941-01
NCGC00094941-02
NChemBio.2007.9-comp7
NINDS_000915
NSC313410
P6801_ALDRICH
P6801_SIGMA
PFA & rIFN.alpha.A
Phgosphonocarboxylic acid
Phosphinecarboxylic acid, dihydroxy-, oxide
Phosphinecarboxylic acid, dihydroxy-, oxide, trisodium salt
Phosphinecarboxylic acid, dihydroxy-, oxide, trisodium salt, hexahydrate
Phosphonoformate
Phosphonoformate(trisodium) & Recombinant Alpha-A Interferon
Phosphonoformic acid
Phosphonoformic acid & IFN-.ALPHA.
Phosphonoformic acid trisodium salt hexahydrate
Phosphonoformic acid, trisodium salt
Phosphonoformic acid, trisodium salt, hexahydrate
Phosphonomethanoic acid
Prestwick_1024
SPBio_000735
SPECTRUM1502019
Sodium phosphonoformate tribasic hexahydrate
Spectrum2_000668
Spectrum3_001484
Spectrum4_000840
Spectrum5_000932
Spectrum_001359
Triapten
Trisodium carboxyphosphate
Trisodium phosphonoformate
Trisodium phosphonoformate hexahydrate
Trisodium phosphonoformte hexahydrate
UNII-364P9RVW4X
UNII-964YS0OOG1
Virudin
dihydroxyphosphanecarboxylic acid oxide
foscarnet
foscarnet sodium hexahydrate
phosphonomethanoic acid
sodium dioxidophosphanecarboxylate oxide hydrate(3:1:6)
trisodium carboxyphosphate (anhydrous)
trisodium dioxidophosphanecarboxylate oxide
trisodium dioxidophosphinecarboxylate oxide
trisodium phosphonatoformate
trisodium phosphonatoformate hexahydrate
trisodium phosphonoformate (anhydrous)
49
Ganciclovirapproved, investigational15382410-32-03454
Synonyms:
106931-35-5
107910-75-8 (mono-hydrochloride salt)
2'-NDG
2'-Nor-2'-deoxyguanosine
2-(6-Amino-purin-9-ylmethoxy)-propane-1,3-diol
2-Amino-1,9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-6-H-purin-6-one
2-Amino-9-(2-hydroxy-1-hydroxymethyl-ethoxymethyl)-1,9-dihydro-purin-6-one
2-amino-9-((1,3-Dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one
2-amino-9-((1,3-Dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one
2-amino-9-((1,3-Dihydroxypropan-2-yloxy)methyl)-9H-purin-6-ol
2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one
2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one
2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-9H-purin-6-ol
2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)-3H-purin-6-one
2-amino-9-(2-Hydroxy-1-hydroxymethylethoxymethyl)-6,9-dihydro-1H-6-purinone
2-amino-9-(2-hydroxy-1-hydroxymethylethoxymethyl)-6,9-dihydro-1H-6-purinone
2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-1,9-dihydro-6H-purin-6-one
2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-6,9-dihydro-3H-purin-6-one
82410-32-0
86357-12-2
9-((1,3-Dihydroxy-2-propoxy)methyl)guanine
9-((2-Hydroxy-1-(hydroxymethyl)ethoxy)methyl)guanine
9-(1,3-DIHYDROXY-PROPOXYMETHANE)GUANINE
9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine
9-[(1,3-dihydroxy-2-propoxy)methyl]guanine
96551-29-0
AC-12604
AC1L1FZ2
AC1Q52OB
AKOS004119898
BB_NC-1042
BIDD:GT0783
BIOLF-62
BPBio1_000877
BSPBio_000797
BW 759
BW 759U
BW-759U
BW-795
BW-B 759U
Biolf 62
CAS-82410-32-0
CCRIS 9212
CHEBI:465284
CHEMBL182
CID3454
CPD000058324
Citovirax
Cymevan
Cymeven
Cymevene
Cytovene
Cytovene (TN)
Cytovene-IV
D00333
DB01004
DRG-0018
EU-0100539
 
G 2536
G2536_SIGMA
GA2
GANCICLOVIR SODIUM
GCV & 1110U81
GCV & MSL
Ganciclovir
Ganciclovir & C34-dgA immunotoxin
Ganciclovir & D5-dgA immunotoxin
Ganciclovir (JAN/USP/INN)
Ganciclovir [USAN:INN:BAN:JAN]
Ganciclovirum
Ganciclovirum [Latin]
Gancyclovir
Guanine, 9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)- and MSL, neutralizing monoclonal antibody
HHEMG
HMS1570H19
HMS2090K08
HSDB 6512
Hydroxyacyclovir
I07-0010
IN1478
LS-73939
Lopac-G-2536
Lopac0_000539
MB3795
MLS000028481
MLS001077349
MolPort-000-758-398
MolPort-002-507-301
NCGC00015471-01
NCGC00015471-02
NCGC00015471-03
NCGC00015471-06
NCGC00093928-01
NCGC00093928-02
NCGC00168567-01
PDSP1_000816
PDSP2_000803
Prestwick0_000839
Prestwick1_000839
Prestwick2_000839
Prestwick3_000839
Prestwick_1068
RS-21592
SAM002548936
SMP2_000038
SMR000058324
SPBio_002718
ST-605
STK801910
UNII-P9G3CKZ4P5
Virgan
Vitrasert
Vitrasert (TN)
ZINC00001505
Zirgan
ganciclovir
nchembio.87-comp3
50
Ironapproved11657439-89-623925
Synonyms:
02583_FLUKA
12310_ALDRICH
12310_RIEDEL
129048-51-7
14067-02-8
161135-39-3
190454-13-8
195161-83-2
199281-22-6
209309_ALDRICH
209309_SIAL
255637_ALDRICH
266213_ALDRICH
266256_ALDRICH
267945_ALDRICH
267953_ALDRICH
26Fe
338141_ALDRICH
356808_ALDRICH
356824_ALDRICH
356832_ALDRICH
39344-71-3
3ZhP
413054_ALDRICH
443783-52-6
44890_ALDRICH
44890_FLUKA
675141-17-0
70884-35-4
73135-38-3
7439-89-6
8011-79-8
8053-60-9
AC1L2N38
ATW 230
ATW 432
Ancor B
Ancor en 80/150
Armco iron
Atomel 28
Atomel 300M200
Atomel 500M
Atomel 95
Atomiron 44MR
Atomiron 5M
Atomiron AFP 25
Atomiron AFP 5
C00023
C3518_SIAL
C3518_SIGMA
CCRIS 1580
CHEBI:18248
CID23925
Carbonyl iron
Copy Powder CS 105-175
D007501
DB01592
DSP 1000
DSP 128B
DSP 135
DSP 135C
DSP 138
Diseases (animal), iron overload
Diseases, iron overload
EF 1000
EF 250
EFV 200/300
EFV 250
EFV 250/400
EINECS 231-096-4
 
Ed-In-Sol
Eisen
Electrolytic iron
F 60 (metal)
FE
FT 3 (element)
Fe
Fe-40
Fe1+
Feronate
Ferretts
Ferro-Caps
Ferro-Time
Ferrousal
Ferrovac E
Ferrum
Ferrum metallicum
GS 6
HF 2 (element)
HL (iron)
HQ (metal)
HS (iron)
HS 4849
HSDB 604
Hemocyte
Hierro
Hoeganaes ATW 230
Hoeganaes EH
IRMM524A_FLUKA
IRMM524B_FLUKA
IRON
Iron (Fe)
Iron (Fe1+)
Iron ion (Fe+)
Iron ion(1+)
Iron monocation
Iron powder
Iron standard for AAS
Iron(1+)
Iron(1+) ion
Iron(III) nitrate solution
Iron, carbonyl
Iron, electrolytic
Iron, elemental
Iron, ion (Fe1+)
Iron, ion (Fe1+) (8CI,9CI)
Iron, reduced
LOHA
LS-3196
MolPort-003-925-001
NC 100
PZh-1M3
PZh-2
PZh1M1
PZh2M
PZh2M1
PZh2M2
PZh3
PZh3M
PZh4M
PZhO
Reduced iron
Remko
SUY-B 2
Siderol
UNII-E1UOL152H7
Vitedyn-Slo
Yieronia
fer
ferrous iron
hierro

Interventional clinical trials:

(show all 49)
idNameStatusNCT IDPhase
1Imatinib in KIT-negative Systemic MastocytosisCompletedNCT01297777Phase 4
2A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis With HandicapUnknown statusNCT00814073Phase 3
3Study on Mastocytosis for Rupatadine TreatmentCompletedNCT01481909Phase 2, Phase 3
4Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic MastocytosisRecruitingNCT01602939Phase 2, Phase 3
5Midostaurin in Indolent Systemic MastocytosisUnknown statusNCT01920204Phase 2
6Evaluation of Response of Dasatinib to Treat MastocytosisUnknown statusNCT00979160Phase 2
7Imatinib Mesylate (Gleevec) in the Treatment of Systemic SclerosisUnknown statusNCT00555581Phase 2
8Sunitinib® in Patients With Recurrent Ovarian Clear Cell CarcinomaUnknown statusNCT01824615Phase 2
9Everolimus (RAD001) as Therapy for Patients With Systemic MastocytosisCompletedNCT00449748Phase 2
10Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)CompletedNCT00493129Phase 2
11Treatment of Indolent Systemic Mastocytosis With PA101CompletedNCT02478957Phase 2
12Thalidomide in Treating Patients With Relapsed or Progressive Systemic MastocytosisCompletedNCT00769587Phase 2
1317-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic MastocytosisCompletedNCT00132015Phase 2
14Stem Cell Transplantation to Treat Systemic MastocytosisCompletedNCT00006413Phase 2
15A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Blood Related CancersCompletedNCT00109707Phase 1, Phase 2
16Efficacy of AB1010 in Patients With Systemic Indolent MastocytosisCompletedNCT00831974Phase 2
17Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase EnzymesCompletedNCT00171912Phase 2
18Efficacy and Safety of TF002 in Cutaneous MastocytosisCompletedNCT00457288Phase 2
19Phase II Trial of Prophylactic Rituximab Therapy for Prevention of CGVHDCompletedNCT00186628Phase 2
20Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00118352Phase 2
21Ibrutinib in Treating Patients With Advanced Systemic MastocytosisRecruitingNCT02415608Phase 2
22SL-401 in Advanced, High Risk Myeloproliferative Neoplasms (Systemic Mastocytosis, Advanced Symptomatic Hypereosinoophic Disorder, Myelofibrosis, Chronic Myelomonocytic Leukemia)RecruitingNCT02268253Phase 1, Phase 2
23Phase II Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell LeukemiaActive, not recruitingNCT00233454Phase 2
24Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell LeukemiaActive, not recruitingNCT00782067Phase 2
25Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic CancerActive, not recruitingNCT00006251Phase 1, Phase 2
26Obatoclax for Systemic MastocytosisTerminatedNCT00918931Phase 2
27Sunitinib in Treating Patients With Idiopathic MyelofibrosisTerminatedNCT00387426Phase 2
28Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral TherapyCompletedNCT00890747Phase 1
29MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or LeukemiaCompletedNCT01231919Phase 1
30Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (advSM) and Relapsed or Refractory Myeloid MalignanciesRecruitingNCT02561988Phase 1
31A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002RecruitingNCT02808793Phase 1
32A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced MalignanciesRecruitingNCT02571036Phase 1
33Use of Tamoxifen in Systemic MastocytosisUnknown statusNCT01334996
34Patient-Reported Outcome Questionnaire for Systemic MastocytosisCompletedNCT02380222
35Cytokine Production Patterns in Patients With Systemic Mastocytosis Compared With Atopic Dermatitis and Healthy IndividualsCompletedNCT00001760
36Molecular Mechanisms and Diagnosis of MastocytosisCompletedNCT00336076
37Cause and Natural Course of Pediatric-Onset MastocytosisCompletedNCT00050193
38Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without CancerCompletedNCT00112593
39Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell TransplantCompletedNCT01199562
40Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic MalignanciesCompletedNCT01273766
41Diagnostic Value of Bone Marrow Tryptase in Systemic MastocytosisRecruitingNCT02441166
42Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell LeukemiaRecruitingNCT01807598
43Study of Mast Cell PrecursorsRecruitingNCT00001756
44Mast Cell Connect: A Registry for Patients With MastocytosisRecruitingNCT02620254
45Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute LeukemiaRecruitingNCT01869777
46Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With CancerRecruitingNCT00898079
47Pregnancy and Medically Assisted Conception in Rare DiseasesRecruitingNCT02450396
48Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for CancerActive, not recruitingNCT01053494
49Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic MalignanciesActive, not recruitingNCT00014235

Search NIH Clinical Center for Systemic Mastocytosis

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Systemic Mastocytosis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Systemic Mastocytosis:
Peripheral blood-derived hematopoietic stem cells for treatment of systemic mastocytosis
Embryonic/Adult Cultured Cells Related to Systemic Mastocytosis:
Peripheral blood-derived hematopoietic stem cells (family), PMID: 10498605


Cochrane evidence based reviews: mastocytosis, systemic

Genetic Tests for Systemic Mastocytosis

About this section

Genetic tests related to Systemic Mastocytosis:

id Genetic test Affiliating Genes
1 Mast Cell Disease, Systemic27

Anatomical Context for Systemic Mastocytosis

About this section

MalaCards organs/tissues related to Systemic Mastocytosis:

36
Bone, Bone marrow, Liver, Small intestine, Spleen, Myeloid, Skin

Publications for Systemic Mastocytosis

About this section

Articles related to Systemic Mastocytosis:

(show top 50)    (show all 630)
idTitleAuthorsYear
1
CCL2 is a KIT D816V-dependent modulator of the bone marrow microenvironment in systemic mastocytosis. (27856463)
2017
2
A new therapeutic advance for symptomatic systemic mastocytosis? (28069280)
2017
3
Clonal reticulohistiocytosis of the skin and bone marrow associated with systemic mastocytosis and acute myeloid leukaemia. (28074480)
2017
4
Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study. (28069279)
2017
5
Longitudinal Evaluation of Bone Mineral Density and Bone Metabolism Markers in Patients with Indolent Systemic Mastocytosis Without Osteoporosis. (27743017)
2017
6
Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature. (27448981)
2016
7
Well-differentiated systemic mastocytosis showed excellent clinical response to imatinib in the absence of known molecular genetic abnormalities: A case report. (27741105)
2016
8
Comparison of gDNA-based versus mRNA-based KIT D816V mutation analysis reveals large differences between blood andA bone marrow in systemic mastocytosis. (27196380)
2016
9
A case of systemic mastocytosis diagnosed on colonic biopsy. (27772953)
2016
10
Response of patients with indolent systemic mastocytosis to tamoxifen citrate. (26612479)
2016
11
Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis. (28038453)
2016
12
Analytical and clinical validation of an LC-MS/MS method for urine leukotriene E4: A marker of systemic mastocytosis. (26908217)
2016
13
Ileal Pouch Biopsy Triggers Investigation and Diagnosis of Systemic Mastocytosis. (27807556)
2016
14
Kounis syndrome and systemic mastocytosis in a 52-year-old man having surgery. (27486207)
2016
15
Systemic Mastocytosis Causing Refractory Pruritus in a Liver Disease Patient. (27921051)
2016
16
Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice. (27694501)
2016
17
Systemic Mastocytosis as an Unconventional Cause of Variceal Bleeding: Think Outside the Box. (27433408)
2016
18
Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients. (27060898)
2016
19
Kounis syndrome revisited: Systemic mastocytosis and severe coronary artery disease. (27040990)
2016
20
Systemic mastocytosis presenting as occupational IgE-mediated anaphylaxis to pine processionary caterpillar. (27474119)
2016
21
Bone marrow tryptase as a possible diagnostic criterion for adult systemic mastocytosis. (26767494)
2016
22
The Basophil Activation Test Is Not a Useful Screening Tool for Hymenoptera Venom-Related Anaphylaxis in Patients with Systemic Mastocytosis. (27055231)
2016
23
Risk of solid cancer, cardiovascular disease, anaphylaxis, osteoporosis and fractures in patients with systemic mastocytosis: A nationwide population-based study. (27428296)
2016
24
Association between rheumatoid arthritis and systemic mastocytosis: a case report and literature review. (27507661)
2016
25
Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. (27131865)
2016
26
Systemic mastocytosis: A cohort study on clinical characteristics of 136 patients in a large tertiary centre. (26809706)
2016
27
Systemic mastocytosis with generalised skin involvement. (27745878)
2016
28
Clinicopathological characteristics of systemic mastocytosis in the intestine. (27391777)
2016
29
Systemic Mastocytosis with Smoldering Multiple Myeloma: Report of a Case. (27293930)
2016
30
Improving prognostic tools in systemic mastocytosis: Insights from mutations. (27397606)
2016
31
Prostaglandin D2 metabolites as a biomarker of in vivo mast cell activation in systemic mastocytosis and rheumatoid arthritis. (27042302)
2016
32
Multiple vertebral fractures in young man as first manifestation of systemic mastocytosis. (26975512)
2016
33
'Childhood systemic mastocytosis associated with t (8; 21) (q22; q22) acute myeloid leukemia'. (27510692)
2016
34
Beneficial effects of JAK inhibitor therapy in Systemic Mastocytosis. (26847591)
2016
35
Systemic Mastocytosis with Associated Clonal Hematological Non-Mast Cell Lineage Disorder (MDS-RCMD): A Difficult Disease to Diagnose and Treat. (27408369)
2016
36
Impact of centralized evaluation of bone marrow histology in systemic mastocytosis. (26914980)
2016
37
Systemic mastocytosis presenting as cardiac tamponade with CD25(+) pericardial mast cells. (27014452)
2016
38
A new humanized in vivo model of KIT D816V+ advanced systemic mastocytosis monitored using a secreted luciferase. (27783996)
2016
39
CD123 immunostaining patterns in systemic mastocytosis: differential expression in disease subgroups and potential prognostic value. (26678095)
2016
40
Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis. (27416984)
2016
41
A 26-Year-Old Female with Systemic Mastocytosis with Associated Myeloid Neoplasm with Eosinophilia and Abnormalities of PDGFRB, t(4;5)(q21;q33). (27648315)
2016
42
Endocrine manifestations of systemic mastocytosis in bone. (27239674)
2016
43
Resolution of osteosclerosis after alloHCT in systemic mastocytosis. (27512733)
2016
44
Next-generation sequencing in systemic mastocytosis: Derivation of a mutation-augmented clinical prognostic model for survival. (27214377)
2016
45
Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. (27355533)
2016
46
Midostaurin in Advanced Systemic Mastocytosis. (27355555)
2016
47
Ruxolitinib improves symptoms and quality of life in a patient with systemic mastocytosis. (26855781)
2016
48
Osteoporotic spinal burst fracture in a young adult as first presentation of systemic mastocytosis. (27141048)
2016
49
KIT D816V-mutated bone marrow mesenchymal stem cells in indolent systemic mastocytosis are associated with disease progression. (26622064)
2016
50
A variant c-KIT mutation, D816H, fundamental to the sequential development of an ovarian mixed germ cell tumor and systemic mastocytosis with chronic myelomonocytic leukemia. (27781377)
2016

Variations for Systemic Mastocytosis

About this section

Clinvar genetic disease variations for Systemic Mastocytosis:

5
id Gene Variation Type Significance SNP ID Assembly Location
1KITNM_ 000222.2(KIT): c.2459A> G (p.Asp820Gly)SNVPathogenicrs121913682GRCh37Chr 4, 55599333: 55599333

Expression for genes affiliated with Systemic Mastocytosis

About this section
Search GEO for disease gene expression data for Systemic Mastocytosis.

Pathways for genes affiliated with Systemic Mastocytosis

About this section

Pathways related to Systemic Mastocytosis according to GeneCards Suite gene sharing:

(show all 31)
idSuper pathwaysScoreTop Affiliating Genes
19.9KIT, KITLG
29.8PDGFRA, PDGFRB
39.8PDGFRA, PDGFRB
4
Show member pathways
9.6KIT, PDGFRA, PDGFRB
5
Show member pathways
9.5JAK2, KIT, KITLG
6
Show member pathways
9.5FGFR1, KIT, PDGFRB
7
Show member pathways
9.4FGFR1, PDGFRA, PDGFRB
89.4FGFR1, PDGFRA, PDGFRB
9
Show member pathways
9.4FGFR1, PDGFRA, PDGFRB
109.4CD2, KIT, KITLG
11
Show member pathways
9.3KIT, KITLG, PDGFRA, PDGFRB
129.2FGFR1, KIT, PDGFRA, PDGFRB
139.1FGFR1, KITLG, PDGFRA, PDGFRB
149.1CD2, IFNA2, KIT, KITLG
159.0CD2, JAK2, KIT, KITLG
16
Show member pathways
8.9JAK2, KIT, KITLG, PDGFRA, PDGFRB
17
Show member pathways
8.9FGFR1, KIT, KITLG, PDGFRA, PDGFRB
18
Show member pathways
8.9FGFR1, KIT, KITLG, PDGFRA, PDGFRB
19
Show member pathways
8.9FGFR1, KIT, KITLG, PDGFRA, PDGFRB
20
Show member pathways
8.9FGFR1, KIT, KITLG, PDGFRA, PDGFRB
218.9FGFR1, KIT, KITLG, PDGFRA, PDGFRB
22
Show member pathways
8.8FGFR1, JAK2, KIT, PDGFRA, PDGFRB
238.5FGFR1, JAK2, KIT, KITLG, PDGFRA, PDGFRB
24
Show member pathways
8.5FGFR1, JAK2, KIT, KITLG, PDGFRA, PDGFRB
25
Show member pathways
8.5FGFR1, JAK2, KIT, KITLG, PDGFRA, PDGFRB
268.2FGFR1, IFNA2, JAK2, KIT, KITLG, PDGFRA
27
Show member pathways
8.2FGFR1, IFNA2, JAK2, KIT, KITLG, PDGFRA
28
Show member pathways
8.0CD2, FGFR1, JAK2, KIT, KITLG, PDGFRA
29
Show member pathways
8.0CD2, FGFR1, JAK2, KIT, KITLG, PDGFRA
30
Show member pathways
7.7CD2, FGFR1, IFNA2, JAK2, KIT, KITLG
31
Show member pathways
7.7CD2, FGFR1, IFNA2, JAK2, KIT, KITLG

GO Terms for genes affiliated with Systemic Mastocytosis

About this section

Cellular components related to Systemic Mastocytosis according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1intrinsic component of plasma membraneGO:00312269.8PDGFRA, PDGFRB

Biological processes related to Systemic Mastocytosis according to GeneCards Suite gene sharing:

(show all 35)
idNameGO IDScoreTop Affiliating Genes
1ectopic germ cell programmed cell deathGO:003523410.7KIT, KITLG
2embryonic hemopoiesisGO:003516210.7KIT, KITLG
3cardiac myofibril assemblyGO:005500310.6PDGFRA, PDGFRB
4metanephric glomerular capillary formationGO:007227710.6PDGFRA, PDGFRB
5negative regulation of platelet-derived growth factor receptor-beta signaling pathwayGO:200058710.6PDGFRA, PDGFRB
6positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathwayGO:003809110.6PDGFRA, PDGFRB
7positive regulation of tyrosine phosphorylation of Stat5 proteinGO:004252310.5JAK2, KIT
8positive regulation of phosphoprotein phosphatase activityGO:003251610.5JAK2, PDGFRB
9retina vasculature development in camera-type eyeGO:006129810.4PDGFRA, PDGFRB
10cell chemotaxisGO:006032610.4KIT, PDGFRA, PDGFRB
11male gonad developmentGO:000858410.3KIT, KITLG, PDGFRB
12cytokine-mediated signaling pathwayGO:001922110.3IFNA2, JAK2, KIT
13positive regulation of phosphatidylinositol 3-kinase activityGO:004355210.3KIT, PDGFRA, PDGFRB
14platelet-derived growth factor receptor signaling pathwayGO:004800810.2JAK2, PDGFRA, PDGFRB
15positive regulation of tyrosine phosphorylation of STAT proteinGO:004253110.2IFNA2, JAK2, KIT
16positive regulation of tyrosine phosphorylation of Stat3 proteinGO:004251710.2IFNA2, JAK2, KIT
17myeloid progenitor cell differentiationGO:000231810.2KIT, TET2
18cell migrationGO:001647710.1FGFR1, JAK2, PDGFRB
19positive regulation of cell migrationGO:003033510.0JAK2, KIT, PDGFRA, PDGFRB
20homeostasis of number of cellsGO:00488729.9ASXL1, TET2
21positive regulation of phospholipase C activityGO:00108639.9FGFR1, KIT, PDGFRA, PDGFRB
22positive regulation of MAP kinase activityGO:00434069.9FGFR1, KIT, KITLG, PDGFRB
23hemopoiesisGO:00300979.6ASXL1, KIT, TET2
24phosphatidylinositol phosphorylationGO:00468549.6FGFR1, KIT, KITLG, PDGFRA, PDGFRB
25phosphatidylinositol-mediated signalingGO:00480159.6FGFR1, KIT, KITLG, PDGFRA, PDGFRB
26transmembrane receptor protein tyrosine kinase signaling pathwayGO:00071699.6KIT, PDGFRA, PDGFRB
27peptidyl-tyrosine phosphorylationGO:00181089.6FGFR1, JAK2, KIT, PDGFRA, PDGFRB
28phosphorylationGO:00163109.6FGFR1, JAK2, KIT, PDGFRA, PDGFRB
29positive regulation of phosphatidylinositol 3-kinase signalingGO:00140689.5FGFR1, JAK2, KIT, PDGFRA, PDGFRB
30protein autophosphorylationGO:00467779.5FGFR1, JAK2, KIT, PDGFRA, PDGFRB
31regulation of phosphatidylinositol 3-kinase signalingGO:00140669.4FGFR1, KIT, KITLG, PDGFRA, PDGFRB
32protein phosphorylationGO:00064689.4FGFR1, JAK2, KIT, PDGFRA, PDGFRB
33MAPK cascadeGO:00001659.3FGFR1, JAK2, KIT, KITLG, PDGFRA, PDGFRB
34positive regulation of cell proliferationGO:00082849.2FGFR1, JAK2, KIT, KITLG, PDGFRA, PDGFRB
35positive regulation of GTPase activityGO:00435479.2FGFR1, JAK2, KIT, KITLG, PDGFRA, PDGFRB

Molecular functions related to Systemic Mastocytosis according to GeneCards Suite gene sharing:

(show all 12)
idNameGO IDScoreTop Affiliating Genes
1platelet-derived growth factor bindingGO:004840710.7PDGFRA, PDGFRB
2platelet-derived growth factor receptor bindingGO:000516110.7PDGFRA, PDGFRB
3phosphatidylinositol 3-kinase bindingGO:004354810.6JAK2, PDGFRB
4vascular endothelial growth factor bindingGO:00380859.8PDGFRA, PDGFRB
5phosphatidylinositol-4,5-bisphosphate 3-kinase activityGO:00469349.7FGFR1, KIT, KITLG, PDGFRA, PDGFRB
6kinase activityGO:00163019.6FGFR1, JAK2, KIT, PDGFRA, PDGFRB
7nucleotide bindingGO:00001669.6FGFR1, JAK2, KIT, PDGFRA, PDGFRB
8protein kinase activityGO:00046729.4FGFR1, JAK2, KIT, PDGFRA, PDGFRB
9protein tyrosine kinase activityGO:00047139.4FGFR1, JAK2, KIT, PDGFRA, PDGFRB
10transmembrane receptor protein tyrosine kinase activityGO:00047149.2FGFR1, KIT, PDGFRA, PDGFRB
11Ras guanyl-nucleotide exchange factor activityGO:00050889.0FGFR1, JAK2, KIT, KITLG, PDGFRA, PDGFRB
12protein bindingGO:00055155.9ASXL1, CD2, FGFR1, FIP1L1, HDC, IFNA2

Sources for Systemic Mastocytosis

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet